Literature DB >> 6192218

Interferon production and natural killer (NK) activity in leukocyte cultures from multiple sclerosis patients.

G Vervliet, H Claeys, H Van Haver, H Carton, C Vermylen, E Meulepas, A Billiau.   

Abstract

Peripheral blood leukocyte (PBL) cultures from only 37% of MS patients produced detectable HuIFN-gamma in response to ConA as opposed to 85% of the cultures derived from normal blood donors. However, the yields in patient-derived cultures that were responsive, were not lower than those in cultures from controls. Production of HuIFN-alpha after stimulation with Sendai virus was not aberrant in cells taken from MS patients. The difference in HuIFN-gamma response rate between MS and normal donor-derived cells was more pronounced when DR2+ carriers were compared amongst each other than when DR2-k carriers were compared. Among the MS patients, the failure of PBLs to produce HuIFN-gamma in response to ConA was not correlated with age, sex, disease duration and type of disease. However, positive correlations were found with current disability indices and past disease progression rates. Unstimulated NK-activities of MS patient-derived PBLs were not different from those of normal donor-derived cells. the degree of augmentation of the activity by stimulation with ConA and interferon-alpha was also normal. Within the MS patients group, but not in the control group, there was a trend for DR2+ carriers to have lower spontaneous and stimulated NK-activities than DR2- individuals.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6192218     DOI: 10.1016/0022-510x(83)90133-8

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

1.  Subsets of T lymphocytes in relation to T lymphocyte function in multiple sclerosis.

Authors:  J C Craig; S A Hawkins; M W Swallow; J A Lyttle; V H Patterson; J D Merrett; M Haire
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

2.  Double blind study of intrathecal beta-interferon in multiple sclerosis: clinical and laboratory results.

Authors:  C Milanese; A Salmaggi; L La Mantia; A Campi; M Eoli; M Savoiardo; G Bianchi; A Nespolo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

3.  Transgenic mouse model for central nervous system demyelination.

Authors:  T Yoshioka; L Feigenbaum; G Jay
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

4.  Normal T cell subsets and lymphocyte activity in multiple sclerosis.

Authors:  M M Albala; D Davignon; L D Fast; D D Clark
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

5.  Influence of prostaglandin E2 and indomethacin on interferon-gamma production by cultured peripheral blood leukocytes of multiple sclerosis patients and healthy donors.

Authors:  G Vervliet; H Deckmyn; H Carton; A Billiau
Journal:  J Clin Immunol       Date:  1985-03       Impact factor: 8.317

Review 6.  Interferons in multiple sclerosis. A review of the evidence.

Authors:  H S Panitch
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

7.  Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro.

Authors:  R L Hirsch; H S Panitch; K P Johnson
Journal:  J Clin Immunol       Date:  1985-11       Impact factor: 8.317

8.  In vitro correction of the interleukin-2 and interferon-gamma defect in multiple sclerosis.

Authors:  G Vervliet; L Schandené
Journal:  Clin Exp Immunol       Date:  1985-09       Impact factor: 4.330

9.  Interferon-gamma production by peripheral blood leucocytes from patients with multiple sclerosis and other neurological diseases.

Authors:  G Vervliet; H Carton; A Billiau
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

10.  Interferon production by cultured peripheral leucocytes of MS patients.

Authors:  G Vervliet; H Carton; E Meulepas; A Billiau
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.